Skip to main content
Clinical Trials/RBR-22zvxw
RBR-22zvxw
Not yet recruiting
未知

Cone-beam computed tomography guided percutaneous cryoablation approach of bone metastases of endocrine tumors - BONEMET-CRYO: bone metastases - cryoablation

Instituto de Radiologia do Hospital das Clínicas / Faculdade de Medicina da Universidade de São Paulo0 sitesJuly 3, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Instituto de Radiologia do Hospital das Clínicas / Faculdade de Medicina da Universidade de São Paulo
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 3, 2018
End Date
TBD
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
Instituto de Radiologia do Hospital das Clínicas / Faculdade de Medicina da Universidade de São Paulo

Eligibility Criteria

Inclusion Criteria

  • patients with bone metastases diagnosis evidenced by imaging exams (CT, MRI and/or PET\-CT) and secondary to: papillary, folicular or medullary thyroid cancer; adrenal carcinoma; neuroendocrine carcinomas; metastatic bone lesions associated with: pain; risk of fracture; risk of spinal cord compression; hypercalcemia; age over or equal 18 years old; performance status (ECOG) of 0, 1, 2 or 3; life expectation over one month; patients must present pain symptoms from bone metastases and / or localized in a region of imminent risk of instability / fracture that may progress to neurological complication (for example, vertebral metastases) or functional impairment (for example, acetabular metastases); all patients must present diagnosis confirmation from metastases biopsy; the same treated patients can be treated again if they present new lesions during the study; all patients must be evaluated for treatment indication by a multidisciplinary team; the metastatic lesions may be located at the axial skeleton, costal arches, shoulder or pelvic girdle; each bone metastases assigned for treatment must be biopsy\-proven and / or presenting elevation of thyroglobulin or calcitonin levels in the needle wash, if thyroid carcinoma is present; all patients must present five symptomatic bone metastases maximum; all selected metastases must have 7\.0 cm diameter maximum;

Exclusion Criteria

  • age bellow 18 years\-old; active anticoagulant treatment
  • non\-conclusive or benign cytologic specimens
  • pregnancy or breast\-feeding undifferentiated thyroid neoplasia (anaplastic)

Outcomes

Primary Outcomes

Not specified

Similar Trials